Pharmacokinetics and muscle histopathology of intramuscular valproate

Bruno V. Gallo, Jeremy D. Slater, Cynthia Toledo, John DeToledo, R. Eugene Ramsay

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To determine the safety and pharmacokinetics of parenteral sodium valproate healthy mature greyhound dogs, were given intramuscular injections following intravenous injections. Dosings intravenously and intramuscularly were at 20, 40 and 60 mg/kg in the three groups. Intravenous infusion rates were constant. Sodium valproate solution concentrations of 300, 400 and 500 mg/ml were administered. Intramuscular valproate was quickly absorbed. Bio- availability approached 70%. Half life of 120 min was calculated. Toxic muscle necrosis was observed at all concentrations. Dosing valproate intramuscularly in humans is problematic in view of the muscle damage. Despite tissue damage sodium valproate was well absorbed intramuscularly. The intravenous injection of valproate at high concentrations, large doses and fast infusion rates produced no evidence of cardiotoxicity and levels of 1811 μg/ml.

Original languageEnglish
Pages (from-to)11-15
Number of pages5
JournalEpilepsy Research
Volume28
Issue number1
DOIs
StatePublished - Jul 1 1997

Fingerprint

Valproic Acid
Pharmacokinetics
Muscles
Intravenous Injections
Poisons
Intramuscular Injections
Intravenous Infusions
Half-Life
Necrosis
Dogs
Safety

Keywords

  • Inflammation
  • Intramuscular
  • Intravenous
  • Muscle necrosis
  • Pharmacokinetic
  • Valproate

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology

Cite this

Gallo, B. V., Slater, J. D., Toledo, C., DeToledo, J., & Ramsay, R. E. (1997). Pharmacokinetics and muscle histopathology of intramuscular valproate. Epilepsy Research, 28(1), 11-15. https://doi.org/10.1016/S0920-1211(97)00027-2

Pharmacokinetics and muscle histopathology of intramuscular valproate. / Gallo, Bruno V.; Slater, Jeremy D.; Toledo, Cynthia; DeToledo, John; Ramsay, R. Eugene.

In: Epilepsy Research, Vol. 28, No. 1, 01.07.1997, p. 11-15.

Research output: Contribution to journalArticle

Gallo, BV, Slater, JD, Toledo, C, DeToledo, J & Ramsay, RE 1997, 'Pharmacokinetics and muscle histopathology of intramuscular valproate', Epilepsy Research, vol. 28, no. 1, pp. 11-15. https://doi.org/10.1016/S0920-1211(97)00027-2
Gallo, Bruno V. ; Slater, Jeremy D. ; Toledo, Cynthia ; DeToledo, John ; Ramsay, R. Eugene. / Pharmacokinetics and muscle histopathology of intramuscular valproate. In: Epilepsy Research. 1997 ; Vol. 28, No. 1. pp. 11-15.
@article{2349c53a8995423cb7fbb7875bb0a69b,
title = "Pharmacokinetics and muscle histopathology of intramuscular valproate",
abstract = "To determine the safety and pharmacokinetics of parenteral sodium valproate healthy mature greyhound dogs, were given intramuscular injections following intravenous injections. Dosings intravenously and intramuscularly were at 20, 40 and 60 mg/kg in the three groups. Intravenous infusion rates were constant. Sodium valproate solution concentrations of 300, 400 and 500 mg/ml were administered. Intramuscular valproate was quickly absorbed. Bio- availability approached 70{\%}. Half life of 120 min was calculated. Toxic muscle necrosis was observed at all concentrations. Dosing valproate intramuscularly in humans is problematic in view of the muscle damage. Despite tissue damage sodium valproate was well absorbed intramuscularly. The intravenous injection of valproate at high concentrations, large doses and fast infusion rates produced no evidence of cardiotoxicity and levels of 1811 μg/ml.",
keywords = "Inflammation, Intramuscular, Intravenous, Muscle necrosis, Pharmacokinetic, Valproate",
author = "Gallo, {Bruno V.} and Slater, {Jeremy D.} and Cynthia Toledo and John DeToledo and Ramsay, {R. Eugene}",
year = "1997",
month = "7",
day = "1",
doi = "10.1016/S0920-1211(97)00027-2",
language = "English",
volume = "28",
pages = "11--15",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics and muscle histopathology of intramuscular valproate

AU - Gallo, Bruno V.

AU - Slater, Jeremy D.

AU - Toledo, Cynthia

AU - DeToledo, John

AU - Ramsay, R. Eugene

PY - 1997/7/1

Y1 - 1997/7/1

N2 - To determine the safety and pharmacokinetics of parenteral sodium valproate healthy mature greyhound dogs, were given intramuscular injections following intravenous injections. Dosings intravenously and intramuscularly were at 20, 40 and 60 mg/kg in the three groups. Intravenous infusion rates were constant. Sodium valproate solution concentrations of 300, 400 and 500 mg/ml were administered. Intramuscular valproate was quickly absorbed. Bio- availability approached 70%. Half life of 120 min was calculated. Toxic muscle necrosis was observed at all concentrations. Dosing valproate intramuscularly in humans is problematic in view of the muscle damage. Despite tissue damage sodium valproate was well absorbed intramuscularly. The intravenous injection of valproate at high concentrations, large doses and fast infusion rates produced no evidence of cardiotoxicity and levels of 1811 μg/ml.

AB - To determine the safety and pharmacokinetics of parenteral sodium valproate healthy mature greyhound dogs, were given intramuscular injections following intravenous injections. Dosings intravenously and intramuscularly were at 20, 40 and 60 mg/kg in the three groups. Intravenous infusion rates were constant. Sodium valproate solution concentrations of 300, 400 and 500 mg/ml were administered. Intramuscular valproate was quickly absorbed. Bio- availability approached 70%. Half life of 120 min was calculated. Toxic muscle necrosis was observed at all concentrations. Dosing valproate intramuscularly in humans is problematic in view of the muscle damage. Despite tissue damage sodium valproate was well absorbed intramuscularly. The intravenous injection of valproate at high concentrations, large doses and fast infusion rates produced no evidence of cardiotoxicity and levels of 1811 μg/ml.

KW - Inflammation

KW - Intramuscular

KW - Intravenous

KW - Muscle necrosis

KW - Pharmacokinetic

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=0030740768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030740768&partnerID=8YFLogxK

U2 - 10.1016/S0920-1211(97)00027-2

DO - 10.1016/S0920-1211(97)00027-2

M3 - Article

C2 - 9255595

AN - SCOPUS:0030740768

VL - 28

SP - 11

EP - 15

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 1

ER -